Strengths

High current and quick ratios indicate ample near-term liquidity versus peers, reducing refinancing pressure despite weaker operating performance.

Low debt-to-equity suggests a comparatively light balance-sheet burden, which can preserve flexibility relative to more levered peers in the same niche.

Weaknesses

Negative ROIC indicates capital is not yet generating peer-competitive returns, implying structurally weak value creation versus profitable medtech peers.

A very long cash conversion cycle ties up working capital, making cash generation slower than peers and constraining reinvestment capacity.

Net debt to EBITDA above one despite limited earnings power signals leverage is less absorbable than peers with stronger operating cash flow.

Missing margin disclosure limits precision, but the available profitability signal remains materially below peers that sustain positive operating margins.

Opportunities

If working-capital discipline improves, the long cash conversion cycle could compress materially, lifting liquidity efficiency toward peer norms.

Balance-sheet flexibility could support selective investment or restructuring, allowing NEOV to narrow the gap with better-capitalized peers over time.

Any future margin disclosure improvement would likely re-rate the company versus peers because current returns already embed a low base.

Threats

Persistent negative ROIC raises the risk that peers compound value faster, widening the structural performance gap over a two-to-five-year horizon.

Extended cash conversion cycles can force higher working-capital funding needs, leaving NEOV more exposed than peers to demand or supply shocks.

If earnings remain weak, even modest leverage can become more constraining than at peers with stronger cash generation and lower funding risk.

Overall Score

NEOV’s peer positioning is weakened by negative returns on capital and slow cash conversion, while liquidity is the main offset rather than a durable competitive advantage.